Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
2.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I.

Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.

PMID:
31143521
3.

Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.

Costa-García M, Ataya M, Moraru M, Vilches C, López-Botet M, Muntasell A.

Front Immunol. 2019 Apr 3;10:687. doi: 10.3389/fimmu.2019.00687. eCollection 2019.

4.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
5.

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A.

Clin Cancer Res. 2018 Aug 1;24(15):3717-3728. doi: 10.1158/1078-0432.CCR-17-3509. Epub 2018 Apr 17.

6.

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L.

Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Review.

7.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

8.

Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System.

Pupuleku A, Costa-García M, Farré D, Hengel H, Angulo A, Muntasell A, López-Botet M.

Front Immunol. 2017 Oct 24;8:1317. doi: 10.3389/fimmu.2017.01317. eCollection 2017.

9.

Life-Long Neurogenic Activity of Individual Neural Stem Cells and Continuous Growth Establish an Outside-In Architecture in the Teleost Pallium.

Furlan G, Cuccioli V, Vuillemin N, Dirian L, Muntasell AJ, Coolen M, Dray N, Bedu S, Houart C, Beaurepaire E, Foucher I, Bally-Cuif L.

Curr Biol. 2017 Nov 6;27(21):3288-3301.e3. doi: 10.1016/j.cub.2017.09.052. Epub 2017 Oct 26.

10.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

11.

Impact of Zygosity on Bimodal Phenotype Distributions.

Holst-Hansen T, Abad E, Muntasell A, López-Botet M, Jensen MH, Trusina A, Garcia-Ojalvo J.

Biophys J. 2017 Jul 11;113(1):148-156. doi: 10.1016/j.bpj.2017.05.010.

12.

Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.

López-Montañés M, Alari-Pahissa E, Sintes J, Martínez-Rodríguez JE, Muntasell A, López-Botet M.

J Immunol. 2017 Jul 15;199(2):656-665. doi: 10.4049/jimmunol.1601574. Epub 2017 Jun 19.

13.

Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation.

López-Botet M, Vilches C, Redondo-Pachón D, Muntasell A, Pupuleku A, Yélamos J, Pascual J, Crespo M.

Front Immunol. 2017 Feb 16;8:166. doi: 10.3389/fimmu.2017.00166. eCollection 2017. Review.

14.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
15.

Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.

Redondo-Pachón D, Crespo M, Yélamos J, Muntasell A, Pérez-Sáez MJ, Pérez-Fernández S, Vila J, Vilches C, Pascual J, López-Botet M.

J Immunol. 2017 Jan 1;198(1):94-101. Epub 2016 Dec 2.

16.

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.

Sánchez-Martínez D, Lanuza PM, Gómez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martínez-Lostao L, Villalba M, Palomera L, Vilches C, García Marco JA, Pardo J.

Front Immunol. 2016 Oct 27;7:454. eCollection 2016.

17.

Development of the adaptive NK cell response to human cytomegalovirus in the context of aging.

López-Botet M, Muntasell A, Martínez-Rodríguez JE, López-Montañés M, Costa-García M, Pupuleku A.

Mech Ageing Dev. 2016 Sep;158:23-6. doi: 10.1016/j.mad.2016.06.010. Epub 2016 Jun 24. Review.

PMID:
27349430
18.

Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers.

Baía D, Pou J, Jones D, Mandelboim O, Trowsdale J, Muntasell A, López-Botet M.

Eur J Immunol. 2016 Jul;46(7):1681-90. doi: 10.1002/eji.201546149. Epub 2016 Jun 2.

19.

Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets.

Muntasell A, Pupuleku A, Cisneros E, Vera A, Moraru M, Vilches C, López-Botet M.

J Immunol. 2016 May 1;196(9):3818-27. doi: 10.4049/jimmunol.1502438. Epub 2016 Mar 18.

20.

Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.

Muntasell A, López-Botet M.

Clin Cancer Res. 2016 Apr 15;22(8):1831-3. doi: 10.1158/1078-0432.CCR-15-3168. Epub 2016 Feb 22.

21.

Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.

Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M.

Mult Scler. 2016 May;22(6):741-52. doi: 10.1177/1352458515601215. Epub 2015 Sep 11.

PMID:
26362897
22.

NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation.

Moraru M, Black LE, Muntasell A, Portero F, López-Botet M, Reyburn HT, Pandey JP, Vilches C.

J Immunol. 2015 Aug 15;195(4):1676-84. doi: 10.4049/jimmunol.1500872. Epub 2015 Jul 15.

23.

Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Sánchez-Martínez D, Azaceta G, Muntasell A, Aguiló N, Núñez D, Gálvez EM, Naval J, Anel A, Palomera L, Vilches C, Marzo I, Villalba M, Pardo J.

Oncoimmunology. 2015 Jan 9;4(3):e991613. eCollection 2015 Mar.

24.

Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus.

Costa-Garcia M, Vera A, Moraru M, Vilches C, López-Botet M, Muntasell A.

J Immunol. 2015 Mar 15;194(6):2715-24. doi: 10.4049/jimmunol.1402281. Epub 2015 Feb 9.

25.

Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies.

Crespo M, Yelamos J, Redondo D, Muntasell A, Perez-Saéz MJ, López-Montañés M, García C, Torio A, Mir M, Hernández JJ, López-Botet M, Pascual J.

Am J Transplant. 2015 Mar;15(3):806-14. doi: 10.1111/ajt.13010. Epub 2015 Feb 5.

26.

Dynamics of the NK-cell subset redistribution induced by cytomegalovirus infection in preterm infants.

Noyola DE, Alarcón A, Noguera-Julian A, Muntasell A, Muñoz-Almagro C, García J, Mur A, Fortuny C, López-Botet M.

Hum Immunol. 2015 Mar;76(2-3):118-23. doi: 10.1016/j.humimm.2015.01.017. Epub 2015 Jan 27.

PMID:
25636568
27.

New advances in CMV and immunosenescence.

Sansoni P, Vescovini R, Fagnoni FF, Akbar A, Arens R, Chiu YL, Cičin-Šain L, Dechanet-Merville J, Derhovanessian E, Ferrando-Martinez S, Franceschi C, Frasca D, Fulöp T, Furman D, Gkrania-Klotsas E, Goodrum F, Grubeck-Loebenstein B, Hurme M, Kern F, Lilleri D, López-Botet M, Maier AB, Marandu T, Marchant A, Matheï C, Moss P, Muntasell A, Remmerswaal EB, Riddell NE, Rothe K, Sauce D, Shin EC, Simanek AM, Smithey MJ, Söderberg-Nauclér C, Solana R, Thomas PG, van Lier R, Pawelec G, Nikolich-Zugich J.

Exp Gerontol. 2014 Jul;55:54-62. doi: 10.1016/j.exger.2014.03.020. Epub 2014 Apr 3.

28.

The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection.

López-Botet M, Muntasell A, Vilches C.

Semin Immunol. 2014 Apr;26(2):145-51. doi: 10.1016/j.smim.2014.03.002. Epub 2014 Mar 22. Review.

PMID:
24666761
29.

NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus.

Muntasell A, López-Montañés M, Vera A, Heredia G, Romo N, Peñafiel J, Moraru M, Vila J, Vilches C, López-Botet M.

Eur J Immunol. 2013 Dec;43(12):3268-78. doi: 10.1002/eji.201343773. Epub 2013 Oct 9.

30.

Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus.

Martínez-Rodríguez JE, Munné-Collado J, Rasal R, Cuadrado E, Roig L, Ois A, Muntasell A, Baro T, Alameda F, Roquer J, López-Botet M.

Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2653-9. doi: 10.1161/ATVBAHA.113.302163. Epub 2013 Aug 22.

PMID:
23968979
31.

Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction.

Muntasell A, Vilches C, Angulo A, López-Botet M.

Eur J Immunol. 2013 May;43(5):1133-41. doi: 10.1002/eji.201243117. Review.

32.

Priming of NK cell anti-viral effector mechanisms by direct recognition of human cytomegalovirus.

Muntasell A, Costa-Garcia M, Vera A, Marina-Garcia N, Kirschning CJ, López-Botet M.

Front Immunol. 2013 Feb 21;4:40. doi: 10.3389/fimmu.2013.00040. eCollection 2013.

33.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.

Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66. doi: 10.1002/eji.201242752. Epub 2012 Oct 25.

34.

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.

Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7. doi: 10.1111/j.1399-0039.2012.01911.x. Epub 2012 Jun 18.

PMID:
22708664
35.

The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope.

Shikhagaie M, Mercé-Maldonado E, Isern E, Muntasell A, Albà MM, López-Botet M, Hengel H, Angulo A.

J Virol. 2012 Apr;86(8):4091-101. doi: 10.1128/JVI.06291-11. Epub 2012 Feb 15.

36.

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis.

Romo N, Fitó M, Gumá M, Sala J, García C, Ramos R, Muntasell A, Masiá R, Bruguera J, Subirana I, Vila J, de Groot E, Elosua R, Marrugat J, López-Botet M.

Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2314-21. doi: 10.1161/ATVBAHA.111.233288. Epub 2011 Aug 4.

PMID:
21817101
37.

Genetic adaptation of the antibacterial human innate immunity network.

Casals F, Sikora M, Laayouni H, Montanucci L, Muntasell A, Lazarus R, Calafell F, Awadalla P, Netea MG, Bertranpetit J.

BMC Evol Biol. 2011 Jul 11;11:202. doi: 10.1186/1471-2148-11-202.

38.

Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization.

Romo N, Magri G, Muntasell A, Heredia G, Baía D, Angulo A, Guma M, López-Botet M.

J Leukoc Biol. 2011 Oct;90(4):717-26. doi: 10.1189/jlb.0311171. Epub 2011 Jul 8.

PMID:
21742939
39.

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.

Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, López-Botet M.

Blood. 2011 Jan 20;117(3):848-56. doi: 10.1182/blood-2010-08-301374. Epub 2010 Oct 28.

40.

Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis.

Camiña-Tato M, Morcillo-Suárez C, Bustamante MF, Ortega I, Navarro A, Muntasell A, López-Botet M, Sánchez A, Carmona P, Julià E, Tortola MT, Audí L, Oksenberg JR, Martin R, Montalban X, Comabella M.

J Immunol. 2010 Nov 1;185(9):5392-404. doi: 10.4049/jimmunol.1000102. Epub 2010 Oct 4. Erratum in: J Immunol. 2011 Aug 1;187(3):1518-21.

41.

Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection.

Muntasell A, Magri G, Pende D, Angulo A, López-Botet M.

Blood. 2010 Jun 24;115(25):5170-9. doi: 10.1182/blood-2009-11-256479. Epub 2010 Apr 14.

42.

Balancing selection is the main force shaping the evolution of innate immunity genes.

Ferrer-Admetlla A, Bosch E, Sikora M, Marquès-Bonet T, Ramírez-Soriano A, Muntasell A, Navarro A, Lazarus R, Calafell F, Bertranpetit J, Casals F.

J Immunol. 2008 Jul 15;181(2):1315-22.

43.

T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes.

Muntasell A, Berger AC, Roche PA.

EMBO J. 2007 Oct 3;26(19):4263-72. Epub 2007 Sep 6.

44.

MHC class II molecules traffic into lipid rafts during intracellular transport.

Poloso NJ, Muntasell A, Roche PA.

J Immunol. 2004 Oct 1;173(7):4539-46.

45.

Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.

Muntasell A, Carrascal M, Alvarez I, Serradell L, van Veelen P, Verreck FA, Koning F, Abian J, Jaraquemada D.

J Immunol. 2004 Jul 15;173(2):1085-93.

46.

HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.

Muntasell A, Carrascal M, Serradell L, Veelen Pv Pv, Verreck F, Koning F, Raposo G, Abián J, Jaraquemada D.

J Immunol. 2002 Nov 1;169(9):5052-60.

47.

HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.

Serradell L, Muntasell A, Catálfamo M, Martí M, Costa M, de Préval C, Jaraquemada D.

Tissue Antigens. 1999 May;53(5):447-58.

PMID:
10372540

Supplemental Content

Loading ...
Support Center